Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
09:59 | AstraZeneca links with Absci on AI for biologics discovery | ||
Fr | MSD, Amgen back patient data specialist Culmination Bio | ||
Fr | FDA starts review of Padcev/Keytruda for bladder cancer | ||
Fr | AZ drops two trials aimed at expanding Lokelma's label | ||
Fr | Cybin preps for ph3 as psychedelic clears depression trial | ||
Do | AbbVie agrees $10.1bn deal to buy ImmunoGen | ||
Do | Could high HDL-cholesterol raise dementia risk? | ||
Do | FDA elevates chief scientist Bumpus to the number two role | ||
Do | Astellas builds case for menopause drug fezolinetant | ||
Do | UK Biobank releases largest-ever genome sequencing dataset | ||
Mi | Start-up Cradle tucks in $24m for protein engineering AI | ||
Mi | AbbVie cues up filing for c-Met ADC in lung cancer | ||
Mi | FDA kicks off review of Karuna's schizophrenia drug KarXT | ||
Mi | Startup Cradle tucks in $24m for protein engineering AI | ||
Mi | CSL, Arcturus get first approval for self-assembling RNA jab | ||
Mi | Shine rubs off Argenx after Vyvgart Hytrulo fails trial | ||
Di | FDA launches wide probe into CAR-T therapy safety | ||
Di | Boehringer puts IBM's genAI into its antibody discovery tank | ||
Di | FDA okays first therapy for desmoid tumours from SpringWorks | ||
Di | CRUK charts course to solve UK's poor cancer survival rate | ||
27.11. | EVERSANA brings genAI to medical content approvals | ||
27.11. | Lifeline for Wolman disease kids as NICE backs Alexion drug | ||
27.11. | Dupixent aces second COPD study, setting up FDA filing | ||
27.11. | Is GSK's Blenrep heading for a renaissance? | ||
27.11. | Digital programme improves metabolic health in diabetes |